Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1301 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
1302 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 55
1303 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 26
1304 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy NETHERLANDS 63
1305 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 33
1306 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy KAZAKHSTAN 10
1307 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Italy 53
1308 Apheresis Allogeneic Hodking Lymphoma Hematology 2025 Standard Therapy Belgium 62
1309 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 54
1310 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 66
1311 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Spain 47
1312 Apheresis Allogeneic T-Cell Lymphoma Hematology 2025 Standard Therapy Poland 25
1313 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Portugal 62
1314 Apheresis Autologous No Data Hematology 2025 Standard Therapy Portugal 65
1315 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 38
1316 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2025 Standard Therapy Germany 60
1317 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 65
1318 Apheresis Autologous Diffuse Large B-Cell Lymphoma Hematology 2025 Standard Therapy Germany 61
1319 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 41
1320 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 73
1321 Apheresis Autologous T-Cell Lymphoma Hematology 2025 Standard Therapy Germany 49
1322 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy NETHERLANDS 61
1323 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 2
1324 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 20
1325 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 5
1326 Apheresis Allogeneic Chronic Granulomatous Disease Hematology 2025 Standard Therapy USA 2
1327 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Slovakia 56
1328 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1329 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 60
1330 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
1331 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Czechia 42
1332 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 63
1333 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 59
1334 Apheresis Allogeneic Myelodysplasia Hematology 2025 Standard Therapy Germany 47
1335 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 58
1336 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 76
1337 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 55
1338 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
1339 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1340 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Czechia 51
1341 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy United Kingdom 56
1342 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Italy 62
1343 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Norway 59
1344 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Ukraine 24
1345 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy NETHERLANDS 63
1346 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 58
1347 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
1348 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 68
1349 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
1350 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 62
1351 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 5
1352 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Turkey 2
1353 Apheresis Allogeneic Hodgkin's Lymphoma (HL) Hematology 2025 Standard Therapy South Africa 38
1354 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Poland 60
1355 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 72
1356 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 59
1357 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy NETHERLANDS 72
1358 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 74
1359 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 72
1360 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 19
1361 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 62
1362 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Switzerland 25
1363 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 69
1364 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 64
1365 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Lithuania 55
1366 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Greece 42
1367 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy France 55
1368 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 49
1369 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 63
1370 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Portugal 68
1371 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 41
1372 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 64
1373 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 68
1374 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 61
1375 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 73
1376 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 39
1377 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 73
1378 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russian Federation 57
1379 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy BELARUS 22
1380 Apheresis Allogeneic Other Leukemia Hematology 2025 Standard Therapy Belgium 60
1381 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 48
1382 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 20
1383 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Lithuania 51
1384 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
1385 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Denmark 72
1386 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 56
1387 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 63
1388 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 68
1389 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 53
1390 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 70
1391 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 14
1392 Apheresis Allogeneic NHL Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 57
1393 Apheresis Allogeneic NHL Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 49
1394 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Russian Federation 43
1395 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 76
1396 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Belgium 63
1397 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 63
1398 Apheresis Allogeneic Other Leukemia, Specify, CNL Hematology 2025 Standard Therapy USA 70
1399 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 53
1400 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Iran 8
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?